Analysts Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) PT at $8.50

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $8.50.

A number of research analysts recently weighed in on ALXO shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a report on Wednesday, December 18th. Jefferies Financial Group lowered shares of ALX Oncology from a “buy” rating to a “hold” rating and cut their price objective for the company from $12.00 to $2.00 in a research report on Thursday, December 19th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of ALX Oncology in a research report on Wednesday, December 18th.

ALX Oncology Stock Down 2.1 %

ALXO stock opened at $1.83 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. ALX Oncology has a 12 month low of $1.19 and a 12 month high of $17.83. The company has a fifty day moving average price of $1.51 and a 200 day moving average price of $3.14. The company has a market cap of $96.52 million, a price-to-earnings ratio of -0.61 and a beta of 1.04.

Insider Buying and Selling at ALX Oncology

In related news, Director Rekha Hemrajani purchased 30,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were acquired at an average cost of $1.55 per share, with a total value of $46,500.00. Following the completion of the purchase, the director now owns 33,000 shares of the company’s stock, valued at $51,150. The trade was a 1,000.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 33.40% of the stock is owned by company insiders.

Institutional Trading of ALX Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP raised its position in shares of ALX Oncology by 423.0% during the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock valued at $3,833,000 after buying an additional 514,133 shares during the last quarter. Privium Fund Management B.V. boosted its holdings in shares of ALX Oncology by 28.2% in the 3rd quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock worth $926,000 after acquiring an additional 112,093 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of ALX Oncology by 87.2% during the second quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock worth $2,642,000 after purchasing an additional 204,100 shares during the last quarter. XTX Topco Ltd bought a new stake in ALX Oncology during the 3rd quarter worth about $578,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of ALX Oncology in the second quarter valued at approximately $1,834,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.